SCHEMBL5283701

SCHEMBL5283701

CC1CCN(C(=O)C2CCCN(S(=O)(=O)c3ccccc3Cl)C2)CC1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.64
HTT P42858 5/20 0.59
NPSR1 Q6W5P4 1/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
LMNA P02545 5/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.54
GAA P10253 2/20 0.53
HSD11B1 P28845 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5286176 0.90 POLB (0.65) POLBHTTNPSR1KMT2AMEN1
SCHEMBL5246776 0.90 POLB (0.75) POLBHTTNPSR1KMT2AMEN1
SCHEMBL5283246 0.87 POLB (0.62) POLBHTTKMT2AMEN1LMNA
SCHEMBL5242741 0.86 POLB (0.64) POLBHTTKMT2AMEN1LMNA
SCHEMBL5242301 0.82 POLB (0.58) POLBHTTKMT2AMEN1LMNA
SCHEMBL5242303 0.82 POLB (0.58) POLBHTTKMT2AMEN1LMNA
SCHEMBL5243117 0.82 AKR1C3 (0.67) POLBHTTKMT2AMAPTALDH1A1
SCHEMBL5243114 0.82 AKR1C3 (0.67) POLBHTTKMT2AMAPTALDH1A1
SCHEMBL5244741 0.82 AKR1C3 (0.67) POLBHTTKMT2AMAPTALDH1A1
SCHEMBL1712959 0.81 AKR1C3 (0.65) POLBHTTKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 EP claimed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 WO claimed
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 EP disclosed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 WO disclosed
US-20060199816-A1 Aryl sulfonyl piperidines GILLESPIE PAUL 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199816-A1 Aryl sulfonyl piperidines GPR119, SLC5A2, GLS2 POLB 3997/4885HTT 1751/4885NPSR1 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.